Frederick Raal to Phenotype
This is a "connection" page, showing publications Frederick Raal has written about Phenotype.
Connection Strength
1,791
-
Obesity phenotypes and dyslipidemia in adults from four African countries: An H3Africa AWI-Gen study. PLoS One. 2025; 20(1):e0316527.
Score: 0,232
-
Evolocumab Treatment in Pediatric Patients With Homozygous Familial Hypercholesterolemia: Pooled Data From Three Open-Label Studies. Arterioscler Thromb Vasc Biol. 2024 May; 44(5):1156-1164.
Score: 0,219
-
Cascade Screening for Familial Hypercholesterolemia in South Africa: The Wits FIND-FH Program. Arterioscler Thromb Vasc Biol. 2020 11; 40(11):2747-2755.
Score: 0,171
-
Long-term safety and efficacy of alirocumab in South African patients with heterozygous familial hypercholesterolaemia: the ODYSSEY Open-Label Extension study. Cardiovasc J Afr. 2019 Sep/Oct 23; 30(5):279-284.
Score: 0,160
-
Impact of Age on the Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia. Cardiovasc Drugs Ther. 2019 02; 33(1):69-76.
Score: 0,153
-
Familial hypercholesterolemia treatments: Guidelines and new therapies. Atherosclerosis. 2018 10; 277:483-492.
Score: 0,150
-
Statins and other lipid-lowering therapy and pregnancy outcomes in homozygous familial hypercholesterolaemia: A retrospective review of 39 pregnancies. Atherosclerosis. 2018 10; 277:502-507.
Score: 0,150
-
Phenotype diversity among patients with homozygous familial hypercholesterolemia: A cohort study. Atherosclerosis. 2016 May; 248:238-44.
Score: 0,125
-
Homozygous familial hypercholesterolemia: current perspectives on diagnosis and treatment. Atherosclerosis. 2012 Aug; 223(2):262-8.
Score: 0,095
-
Rare dyslipidaemias, from phenotype to genotype to management: a European Atherosclerosis Society task force consensus statement. Lancet Diabetes Endocrinol. 2020 01; 8(1):50-67.
Score: 0,040
-
Familial hypercholesterolaemia workshop for leveraging point-of-care testing and personalised medicine in association with the Lipid and Atherosclerosis Society of Southern Africa. Cardiovasc J Afr. 2019 Sep/Oct; 30(5):297-304.
Score: 0,040
-
Overview of the current status of familial hypercholesterolaemia care in over 60 countries - The EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC). Atherosclerosis. 2018 10; 277:234-255.
Score: 0,037
-
Homozygous Familial Hypercholesterolemia Patients With Identical Mutations Variably Express the LDLR (Low-Density Lipoprotein Receptor): Implications for the Efficacy of Evolocumab. Arterioscler Thromb Vasc Biol. 2018 03; 38(3):592-598.
Score: 0,036
-
The effect of lomitapide on cardiovascular outcome measures in homozygous familial hypercholesterolemia: A modelling analysis. Eur J Prev Cardiol. 2017 11; 24(17):1843-1850.
Score: 0,035
-
Statin therapy in a kindred with both apolipoprotein B and low density lipoprotein receptor gene defects. Atherosclerosis. 1997 Feb 28; 129(1):97-102.
Score: 0,034
-
Proprotein Convertase Subtilisin Kexin Type 9 Inhibition for Autosomal Recessive Hypercholesterolemia-Brief Report. Arterioscler Thromb Vasc Biol. 2016 08; 36(8):1647-50.
Score: 0,032
-
Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society. Eur Heart J. 2014 Aug 21; 35(32):2146-57.
Score: 0,028
-
Integrated guidance on the care of familial hypercholesterolaemia from the International FH Foundation. Eur J Prev Cardiol. 2015 Jul; 22(7):849-54.
Score: 0,028
-
Autosomal recessive hypercholesterolaemia: discrimination of ARH protein and LDLR function in the homozygous FH phenotype. Clin Chim Acta. 2007 Mar; 378(1-2):33-7.
Score: 0,016
-
Lipoprotein(a) in homozygous familial hypercholesterolemia. Arterioscler Thromb Vasc Biol. 2000 Feb; 20(2):522-8.
Score: 0,010